Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Erythropoietin for Chemotherapy-Induced Anemia in Children
NCT05704894Phase 3Not yet recruiting
- Sponsor
- Blau Farmacêutica
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of erythropoietin in Chemotherapy-induced anemia (CIA) (2 arms), sponsored by Blau Farmacêutica. Primary endpoint: Hemoglobin Levels at 12 weeks. Planned start May 2023; status: not yet recruiting.
02
Drugs
erythropoietin
03
Conditions
Chemotherapy-induced anemia (CIA)
Beyond the preview
Go deeper on NCT05704894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704894.